Study demonstrates the importance of a specific type of connection between neurons and may also explain how ketamine shows promise in treating depression.
Combining psychological therapy with ketamine treatments resulted in longer periods of abstinence for those with severe alcohol use disorder, a new study reports.
Ketamine reduces symptoms of depression and suicidal thoughts within four hours of a single treatment, and the effects last for up to two weeks. Additional treatments may prolong the effects, researchers say.
Ketamine's rapid antidepressant action is due to specific synaptic effects, researchers report.
A new statistical model lays groundwork for understanding how ketamine induces an anesthetic response, steps to monitor unconscious patients, and provides new information about brain activity while unconscious.
In the absence of neural activity, BDNF expression can still be activated. The findings shed light on how therapeutic ketamine used has an antidepressant effect and how it works in both the long and short term.
A new study provides novel mechanistic insights into how ketamine exerts its antidepressant effects for those with depression.
The MeCP2 gene influences ketamine's behavioral effect and strengthens synapses, leading to an improvement in the drug's antidepressant effect over time.
A new model of schizophrenia opens the door to a better understanding of, and therapeutic options for brain dysfunction that is at the root of psychosis.
Ketamine and exposure to 60-hertz flickering light show promise as a potentially new, non-invasive therapy to help rejuvenate the aging brain.
One dose of psilocybin, the psychoactive compound found in magic mushrooms, increases dendritic spine density within 24 hours. The neurobiological changes lasted for a month following psilocybin exposure. Additionally, mice subjected to stress showed behavioral improvements and increased neurotransmitter activity after psilocybin exposure.
Mouse study reveals elevated dopamine levels preceded hallucination-like events, and artificially boosting dopamine levels induced more hallucination-like events. The behavioral effects could be blocked by administering haloperidol, an antipsychotic which blocks dopamine. The study sheds light on potential new treatments for psychotic disorders marked by hallucinations.
